Our findings provided evidence that AC021683.2 functions as a lncRNA by regulating BCLAF1 in AML, and revealed that targeting the AC021683.2/BACLAF1/RAD50 axis provides potential strategy for the treatment of resistance to Ara-C in AML. The gene discussed is BCLAF1; the disease is acute myeloid leukemia.